Day Two

Thursday April 22

8:15 am Morning Networking

8:50 am Chair’s Opening Remarks

• John White Vice President, Business Strategy and Commercial Operations, PARATEK PHARMACEUTICALS

Advancing Clinical Superiority of Anti-Infectives to Drive Commercial Success

9:00 am Direct Lytic Agents (DLA): New Medical Modalities for Life- Threatening, Drug-Resistant Infections

• Cara Cassino Executive Vice President of R&D & Chief Medical Officer, ContraFect

9:25 am Building a Pipeline of New Mechanism Antibiotics that Drives Commercial Sustainability through Clinical Superiority

• David Powell Chief Scientific Officer, Summit Therapeutics

9:50 am Q&A/Discussion

• Cara Cassino Executive Vice President of R&D & Chief Medical Officer, ContraFect
• David Powell Chief Scientific Officer, Summit Therapeutics
• John White Vice President, Business Strategy and Commercial Operations, PARATEK PHARMACEUTICALS

10:15 am Virtual Speed Networking

10:45 am Morning Break

Targeting Unmet Medical Need to Ensure Anti-Infective Economic Sustainability

11:15 am BV100 – a Novel Therapy for Antibiotic-Resistant Acinetobacter Infections

• Glenn Dale Chief Development Officer, BioVersys

11:40 am Ensuring Anti-Infective Economic Sustainability by Targeting the Unmet Medical Need

• Angela Talley Vice President of Clinical Development, Spero Therapeutics

12:05 pm Targeted Therapy for Rare Pathogens: Challenges & Opportunities

• David Altarac Chief Medical Officer, Entasis Therapeutics

12:30 pm Q&A/Discussion

• Glenn Dale Chief Development Officer, BioVersys
• Angela Talley Vice President of Clinical Development, Spero Therapeutics
• David Altarac Chief Medical Officer, Entasis Therapeutics
• John White Vice President, Business Strategy and Commercial Operations, PARATEK PHARMACEUTICALS

12:55 pm Lunch & Networking Break

Anti-Infectives of the Future: Discovery Superior Novel Agents to Combat AMR

1:45 pm Obstacles for Discovery & Development of Narrow Spectrum Antimicrobials

• Nrusingh Mohapatra Chief Scientific Officer, Techulon

2:10 pm Novel Investigational Polymyxin MRX-8 with an Improved Safety & Efficacy against Key Gram-Negative Infections

• Mike Gordeev Chief Scientific Officer, MicuRx Pharmaceuticals

2:35 pm Cryptic Metabolites as a New Source of Pharmaceutical Leads

• Mohammad Seyedsayamdost Associate Professor of Chemistry & Molecular Biology, Princeton University

3:00 pm Computational Modelling to Aid Target Discovery

• John George Co-Founder & Chief Scientific Officer, Oppilotech

3:25 pm Q&A/Discussion

• Mike Gordeev Chief Scientific Officer, MicuRx Pharmaceuticals
• Nrusingh Mohapatra Chief Scientific Officer, Techulon
• Mohammad Seyedsayamdost Associate Professor of Chemistry & Molecular Biology, Princeton University
• John George Co-Founder & Chief Scientific Officer, Oppilotech

4:00 pm Chair’s Closing Remarks & End of Anti-Infectives Drug Development Summit